No Data
JCR Pharmaceuticals: Notice regarding revisions to full-year consolidated earnings forecasts
JCR Pharmaceuticals To Go Ex-Dividend On March 28th, 2025 With 10 JPY Dividend Per Share
March 27th (Japan Standard Time) - $JCR Pharmaceuticals(4552.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 10 JPY dividend per share. The ex-
Rating information (Target Price change - part 2) = TORAY INDS INC, M&A Cap ETC
◎ Mizuho Securities (three stages: Buy > Hold > underperform) TORAY INDS INC <3402.T> ―― "Buy" → "Buy", 940 yen → 1100 yen Asahi Kasei <3407.T> ―― "Buy" → "Buy", 1150 yen → 1350 yen Zeon <4205.T> ―― "Buy" → "Buy", 1800 yen → 2000 yen Taiheiyo Cement <5233.T> ―― "Buy" → "Buy", 4300 yen → 4500 yen Yamazaki Baking <2212.T> ―― "Hold" → "Hold", 3400 yen → 2950 yen Sumitomo Dainippon.
February 26 [Today's investment strategy]
[Fisco Selected Stocks] 【Material Stocks】 Pool Corp Japan <4690> 1508 yen (2/25) engages in the rental of pallets, handling, and transport equipment. It was announced that a Share Buyback will be implemented, with a maximum of 0.1 million shares, equivalent to 0.2 billion yen, representing 5.94% of the total shares outstanding. An order for the purchase will be placed on the Tokyo Stock Exchange's ToSTNeT-3 for self-owned stock trading on February 26. Additionally, it was announced that out of the acquired self-owned stock, up to 0.08 million shares will be canceled on March 25.
JCR Pharmaceuticals Begins Construction of New Drug Plant in Kobe, Japan
Focus on JPHD and Akita Silver [Today's individual stock trends]
In the U.S. stock market on the 25th, the Dow Jones Industrial Average rose by 159.95 points to 43,621.16, the Nasdaq Composite Index fell by 260.54 points to 19,026.39, and the Chicago Nikkei 225 Futures dropped by 285 yen to 37,955 yen compared to the daytime in Osaka. The exchange rate is 1 dollar = 149.00-10 yen. In today's Tokyo market, JPHD <2749> announced an upward revision of the Financial Estimates and the introduction of a Shareholder benefit program, along with the upward revision of the revenue, operating income, net profit, and Dividends for the fiscal year ending March 2025.